Caphosol

hideThis article has multiple issues. Please help or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs additional citations for verification. Please help by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources:  –  ·  ·  · scholar · JSTOR (February 2011) (Learn how and when to remove this template message) This article contains content that is written like an advertisement. Please help by removing promotional content and inappropriate external links, and by adding encyclopedic content written from a neutral point of view. (May 2009) (Learn how and when to remove this template message) (Learn how and when to remove this template message)

Caphosol (EUSA Pharma) is a mouth rinse designed to moisten, lubricate and clean the oral cavity including the mucosa of the mouth, tongue and oropharynx which has been shown to prevent and treat oral mucositis in patients receiving radiation therapy or chemotherapy for the treatment of cancer.^{[citation needed]}

Uses[]

Caphosol can be used as an adjunct to standard oral care in the prevention and treatment of the mucositis that may be caused by radiation therapy or high dose chemotherapy. Caphosol can also be used to treat dryness of the mouth and oropharynx (hyposalivation, xerostomia), regardless of the cause and regardless of whether the condition is temporary or permanent.^{[citation needed]}

Clinical evidence[]

There is a lack of good quality evidence for the efficacy of caphosol solution and the only systematic review is funded by the manufacturer and so carries an increased risk of bias.^[1]

Quality evidence for Caphosol effervescent tablets is lacking.

Bone marrow transplant[]

The safety and efficacy of Caphosol has been demonstrated in a double-blind prospective, randomized clinical trial in patients undergoing bone marrow transplantation.^[2] This trial demonstrated that Caphosol, used in conjunction with fluoride treatments, offers significant benefits over standard care, and is a significant adjunct in the management of oral mucositis associated with high-dose chemotherapy and radiation therapy. In this study the duration and severity of oral mucositis, and requirements for opioid medication, were evaluated in 95 patients undergoing bone marrow transplantation. The treatment arm received 4 topical fluoride treatments plus Caphosol, while the control arm received a fluoride rinse (0.01% NaF aqueous solution). Patients were instructed to rinse 4 times per day at the start of cancer treatment and up to 10 times per day if they developed severe oral mucositis. The results showed:

• More than twice as many bone marrow transplant patients avoided oral mucositis by using Caphosol
• Duration of oral mucositis was almost halved in patients using Caphosol
• Caphosol patients used 72% less morphine for pain relief, with nearly 75% of patients requiring no morphine at all.

Head and neck cancer[]

Caphosol has also been associated with low occurrence and severity of oral mucositis in a registry of cancer patients.^[3] The registry data provide further evidence to support the use of Caphosol to treat oral mucositis and suggest that Caphosol is associated with a low occurrence and severity of oral mucositis with high adherence to treatment as well as high levels of satisfaction from both patients and physicians.

The registry analysed the effects of Caphosol in head and neck cancer patients along with the frequency of patient dosing, adherence to treatment, and patient and physician global satisfaction assessments. Patients at risk of oral mucositis were given Caphosol and instructed to rinse 4-10 times daily depending on the severity of the mucositis. Patients and physicians completed questionnaires on the symptoms of oral mucositis, mucositis severity and satisfaction with the treatment.

The results showed that 88% of patients receiving chemotherapy and/or radiotherapy for head and neck cancer who had used Caphosol experienced no or low grade (mild-moderate) oral mucositis, and 44% experienced mild or no oral pain. Furthermore, the vast majority of head and neck cancer patients (79%) and physicians (78%) were satisfied with Caphosol as a treatment for mucositis.

Cancer Therapy Mucositis in Children[]

A a prospective multicenter double blind randomized controlled trial showed no advantages for caphosol and statistically significantly more days of pain and analgesia use for the caphosol arm.^[4]

Using Caphosol[]

Caphosol refers to two different preparations. An effervescent dispersible tablet or two separately packaged aqueous solutions, a phosphate solution (Caphosol A) and a calcium solution (Caphosol B) which, when combined in equal volumes, forms a supersaturated solution of both calcium and phosphate ions. It is doubtful that the effervescent tablet can achieve a supersaturated solution of calcium and phosphate ions. Caphosol is usually used 4 times a day, but can be used up to 10 times a day when symptoms of mucositis are present. Caphosol is usually used for the duration of cancer treatment, unless directed otherwise by a physician. Please note that caphosol is used as an oral rinse and is therefore not "taken". (It is not dangerous/harmful if consumed but consumption should be avoided, according to the manufacturer.)

Price[]

It is a prescription drug. Cash price in California or Oregon is $279.99 as of September 28, 2016 for a week's supply totalling 900 ml of two-part solution. According to the manufacturer, solution consists of:^[5]

• Disodium phosphate 0.052%
• Monosodium phosphate 0.009%
• Calcium chloride 0.052%
• Sodium chloride 0.569%
• Purified water

weight.

Retail price of each of ingredients sold separately not exceed a $20 for a pound as of September 28, 2016.

Interactions with other medicines[]

There are no known interactions with medicines or other products.^{[citation needed]}

References[]

External links[]

• Caphosol UK Website